Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Diabetes Mellitus, Type 2, Hypertension
Phase PHASE1
Enrollment 50
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is assess the safety and performance of the Neurotronic Infusion catheter for treatment of patients with Type 2 Diabetes (T2DM) and hypertension.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Combination Product: Neurotronic Infusion Catheter — Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter

Primary Outcomes

  • Incidence of serious device- and procedure-related complications at 30 days post procedure. (30 Days)
  • Device success (During the procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-04-19
Completion: 2029-01
Eligibility
Age: 21 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Neurotronic, Inc.
Collaborators: Libra Medical
Principal Investigators:
  • John Chen, PhD (STUDY_DIRECTOR) - Neurotronic, Inc.
Contact Information
Study Contact:
Yunlong Zhang, MD
+1 669-203-9308
pzhang@libramed.com
John Chen, PhD
+1 763-273-6100
chenj@neurotronic.com
Guadalupe Perez, MD
Hospital Paitilla Clinicas y Hospitales
Interventions
  • Combination Product: Neurotronic Infusion Catheter — Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
Study Locations (3 sites)
Hospital Paitilla Clinicas y Hospitales, Panama City, 0816-03075 Panama
Hospital Punta Pacifica, Panama City, Panama
Sanatorio Adventista de Asunción, Asunción, Paraguay
Eligibility Criteria
Inclusion Criteria: Subjects must meet all of the following criteria to be eligible for participation in the study: 1. Age ≥ 21 and ≤ 65 years at time of enrollment. 2. Disease diagnosed 2.1 Diagnosed with T2DM with baseline: 1. Fasting plasma glucose ≥ 140 mg/dl (7.8 mmol/l) and ≤ 270 mg/dL (15 mmol/L) 2. HbA1c levels ≥ 7.0% and ≤ 9.0% (53-75 mmol/mol) 3. Triglyceride level \< 400 mg/dL (4.52 mmol/L) 4. On oral anti-hyperglycemic drug regimen of metformin. Subjects may be on additional oral anti-hyperglycemic drug of a different drug class 5. Years of T2DM ≤ 10 years And / Or 2.2 Diagnosed hypertension with baseline: 1. Office blood pressure of SBP of ≥ 140 mmHg and ≤ 180 mmHg and DBP ≥ 90 mmHg 2. Mean 24-hour ambulatory SBP of ≥ 130 mmHg and ≤ 170 mmHg with ≥ 75% valid readings 3. On stable oral anti-hypertension drug regimen consisting of up to a maximum of three drugs 3. BMI between 27.5 and 40 kg/m2 4. C-peptide testing: non-fasting random or stimulated C-peptide ≥ 2 ng/mL (660 pmol/L) 5. Vessel diameter of 3 mm to 7 mm with a minimum arterial treatable length of 20 mm in one or more of the following arteries: * Renal * Hepatic Exclusion Criteria: 1. T1DM or poorly controlled T2DM (defined as HbA1c \> 9.0% or use insulin as medication to control glucose level). 2. Office diastolic blood pressure \< 90 mmHg. 3. Current use of \> 3 hypertension medications. 4. Currently on beta blockers. 5. One or more documented hyperglycemia episodes requiring hospitalization in the 180-day prior to screening date. 6. Prior evidence of hypoglycemia unawareness or serious hypoglycemia with loss of consciousness or confusion sufficient to prevent self-treatment in last 6 months. 7. BMI \> 40 kg/m2. 8. Diagnosed proliferative retinopathy or evidence of peripheral neuropathy. 9. Lack of appropriate treatment site or anatomy precluding the intervention of the target arteries (renal and hepatic artery). 10. History of prior renal or hepatic artery intervention including balloon angioplasty, stenting, etc. 11. Arterial stenosis \>50% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment). 12. Any abnormality or disease in one or more of the target arteries that, per the physician assessment, precludes the safe insertion of the guiding catheter (including, but not limited to, artery aneurysm, excessive tortuosity, calcification). 13. Occlusive peripheral vascular disease that would preclude percutaneous femoral access for the procedure. 14. Known or suspected secondary hypertension, such as Cushing's disease or Cushing's Syndrome, hyperaldosteronism, pheochromocytoma, thyroid and parathyroid abnormalities, history of pre-eclampsia, onset of hypertension prior to the age of 18. 15. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment. 16. Severe or unstable cardiovascular comorbidities, such as AMI or ACS, cardiac valve stenosis, pulmonary embolism, heart failure with NYHA Class III or IV, chronic atrial fibrillation, primary pulmonary hypertension, COPD. 17. Renal transplant, history of nephrectomy or single kidney, renal tumor/cancer, known non-functioning kidney, unequal renal size (\>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function), chronic renal deficiency with eGFR ≤ 60ml/min/1.73m2, or on chronic renal replacement therapy. 18. Prior liver transplant. 19. Any organ transplantation procedures are planned in the 365 days following Index Procedure. 20. Gastrointestinal permanent anatomic alteration surgery. 21. Any surgical procedure within 30 days prior to Index Procedure. 22. Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study: 1. Systemic Corticosteroids 2. Anticonvulsants 3. Centrally acting sympatholytics 23. Bleeding disorders, such as bleeding diathesis, thrombocytopenia, and severe anemia. 24. Use of anticoagulation therapy which cannot be discontinued from 7 days before or 14 days after the Index Procedure. 25. Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the investigator. 26. Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake. 27. Active substance abuse, based on Investigator judgement, including inhaled or injected drugs, within 1 year prior to the initial screening. 28. Significant weight loss within the last 6 months (e.g., \> 10% total body weight loss). 29. Hepatic decompensation defined as the presence of any of the following: 1. Serum albumin less than 3.5 g/dL 2. International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) 3. Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome 4. History of esophageal varices, ascites, or hepatic encephalopathy 30. ALT or AST greater than 200 U/L. 31. Diagnosis of liver cirrhosis. 32. Chronic liver or biliary disease of the following etiology: 1. History or diagnosis of Hepatitis B 2. History or diagnosis of Hepatitis C 3. History or diagnosis of current active autoimmune hepatitis 4. History or diagnosis of primary biliary cholangitis 5. History or diagnosis of primary sclerosing cholangitis 6. History or diagnosis of Wilson's disease 7. History or diagnosis of alpha-1-antitrypsin deficiency 8. History or diagnosis of hemochromatosis 9. History or diagnosis of drug-induced liver disease, as defined on the basis of typical exposure and history. 10. Known bile duct obstruction. 11. Suspected or proven liver cancer 33. History of acute or chronic pancreatitis. 34. Human immunodeficiency virus (HIV). 35. Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT). 36. Systemic infection that the investigator judges would pose unacceptable procedural risks to the subject. 37. Known hypersensitivity to contrast media, nickel and ethanol that cannot be adequately pre-medicated. 38. Subject is depressed or on antidepressants. 39. Pregnancy or breastfeeding or plan to get pregnant in next 12 months. 40. Life expectancy of less than 5 years. 41. Unwilling or unable to comply with the follow-up study requirements. 42. Subjects or their legally authorized representatives unable to provide informed consent. 43. Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety. 44. Currently participation in another pre-market drug or medical device clinical study.
Conditions Open-angle Glaucoma, Pseudoexfoliation G...
Phase NA
Enrollment 80
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to determine whether a combination of vitamins (B6, B9, B12, and choline) can help protect the eyes of people with glaucoma and slow vision loss. The study will assess whether these vitamins support retinal cells and maintain or improve their function. Adults aged 18 and older with primary open-angle glaucoma (including normal-tension glaucoma) or pseudoexfoliation glaucoma, and those with mild to moderate glaucoma, may be eligible. Participants must meet specific medical criteria and cannot take additional vitamin supplements during the study. Participants will be randomly assigned to one of two groups: one group will take a daily vitamin supplement (B6, B9, B12, and choline) for one year, along with standard glaucoma care, while the other will continue standard care without extra vitamins. The vitamins used are well tolerated at selected doses, with possible mild side effects such as an upset stomach or tingling sensations. They will visit the clinic five times over 12 months (at the start, and at 3, 6, 9, and 12 months) for routine eye tests, including measuring eye pressure, checking vision and visual fields, taking scans of the eye's nerve layers (OCT), and completing an electroretinogram (ERG) to assess retinal function. Blood samples will also be collected. If the vitamins are effective, this could provide an additional strategy alongside current eye pressure lowering treatments to reduce vision loss.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Vitamin B-mix — Daily oral supplementation with: Vitamin B6 (pyridoxine, 25 mg), 1 capsule Vitamin B9 (folic acid, 400 µg) + Vitamin B12 (cyanocobalamin, 1 mg), 2 capsules. Choline (choline bitartrate, 500 mg), 2 capsules Administered alongside standard glaucoma care.
  • Other: Standard Care — Usual glaucoma management (e.g., monitoring and/or IOP-lowering treatments) without additional supplementation.

Primary Outcomes

  • Change in photopic negative response (PhNR) on electroretinography (ERG) (Baseline, third month and twelfth month.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-31
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Collaborators: St. Erik Eye Hospital
Principal Investigators:
  • Rune Brautaset, Professor of Optometry (PRINCIPAL_INVESTIGATOR) - Karolinska Institutet
Contact Information
Study Contact:
Navid Golpour, Medical doctor
+46737085148
navid.golpour@ki.se
James Tribble, Associate Professor
james.tribble@ki.se
Navid Golpour, Medical doctor
+46737085148
navid.golpour@ki.se
St Eriks Ögonsjukhus
Interventions
  • Dietary Supplement: Vitamin B-mix — Daily oral supplementation with: Vitamin B6 (pyridoxine, 25 mg), 1 capsule Vitamin B9 (folic acid, 400 µg) + Vitamin B12 (cyanocobalamin, 1 mg), 2 capsules. Choline (choline bitartrate, 500 mg), 2 capsules Administered alongside standard glaucoma care.
  • Other: Standard Care — Usual glaucoma management (e.g., monitoring and/or IOP-lowering treatments) without additional supplementation.
Study Locations (2 sites)
St Eriks Ögonsjukhus, Stockholm, Stockholm County 11251 Sweden
Karolinska institutet, The Division of Eye and vision., Stockholm, Stockholm County 14186 Sweden
Eligibility Criteria
Eligibility Criteria Inclusion Criteria: Patients with the following characteristics will be eligible for inclusion in the trial: * 18 years or older at the time of inclusion * Diagnosis of Primary Open-Angle Glaucoma (POAG), Normal Tension-Glaucoma (NTG) or Pseudoexfoliation Glaucoma (PEXG) in one or both eyes diagnosticed by an ophthalmologist. * Best corrected Snellen VA of 0.3 or better in the study eye(s) * Two or more reliable VF tests with less than 15% false positives Exclusion Criteria: Patients who meet any of the following criteria will be excluded from participation in the study: * Visual field damage worse than -16dB in the study eye(s) * Eye pressure greater than 35 mmHg in study eye(s) on either of two measurement occasions or a mean pressure of 30 mmHg over two occasions * Any disease affecting retinal function * Neurological or other non-glaucomatous conditions that may affect the visual field * Inability to perform visual field examination * Unwillingness to stop any intake of multivitamins or B vitamin substances * Known allergy or intolerance to B-vitamins * Previous eye surgery, except for uncomplicated cataract surgery * Pregnant or breastfeeding women * Women of childbearing potential who do not use reliable contraception * Any disease or condition likely to prevent long-term follow-up * Cancer diagnosis within the last 5 years (except treated squamous cell carcinoma) * History of liver disease or stomach ulcers * Inability to understand and speak Swedish or English
Conditions Hypertension, Hypertension, Systolic
Phase NA
Enrollment 5320
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

On the basis of new evidence on the relationship between achieved office blood pressure (BP) measurements (OBPM) and the risk of cardiovascular disease (CVD) morbidity and mortality documented in the SPRINT trial, the recent 2017 guidelines of the American College of Cardiology (ACC) and the American Heart Association (AHA) have established lower values of 130/80 mmHg for clinic systolic BP (SBP)/diastolic BP (DBP) as new diagnostic thresholds for hypertension and therapeutic targets for treatment of all individuals aged ≥18 years regardless of age, sex, or concomitant complications including presence of diabetes, chronic kidney disease (CKD), or history of past CVD event. According to these guidelines, the new proposed ambulatory BP measurment (ABPM) thresholds for diagnosis of hypertension in adults are 130/80 and 110/65 mmHg for the awake and asleep SBP/DBP means, respectively. However, the ACC/AHA guidelines do not provide any scientific evidence documenting neither the equivalence between these ABPM thresholds and the 130/80 mmHg cut-off values for OBPM nor the potential improved CVD event-free survival time of the proposed more intensive control of ambulatory BP. Results derived from observational prospective studies consistently document that therapeutic BP targets in hypertensive individuals, i.e., persons at increased CVD risk, should be established in terms of proper control of asleep BP. To date, no prospective randomized study has ever before evaluated which should be the adequate therapeutic ABPM target for most effective reduction of CVD risk. Accordingly, the Tratamiento de Hipertensión Arterial Durante el Sueño study (THADEUS, i.e., Treatment of Hypertension During Sleep) has been designed to prospectively evaluate if "intensive control" of asleep SBP mean proposed by the new ACC/AHA guidelines (\<110 mmHg) in more effective than the so far its "conventional control" (\<120 mmHg) to reduce CVD morbidity and mortality in hypertensive individuals.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Procedure: Treatment of elevated asleep SBP mean — To reduce asleep SBP mean determined by 48h ambulatory blood pressure monitoring up to the randomly assigned target by hypertension treatment intensification when required

Primary Outcomes

  • Vascular events (Median follow-up of 5 years)
  • New-onset type 2 diabetes (Median follow-up of 5 years)
  • New-onset CKD (Median follow-up of 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-02-01
Completion: 2032-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Vigo
Principal Investigators:
  • Ramon C Hermida, PhD (PRINCIPAL_INVESTIGATOR) - University of Vigo
Contact Information
Study Contact:
Ramon C Hermida, PhD
34986812148
rhermida@uvigo.es
José R Fernández, PhD
34986812146
jramon.fernandez@uvigo.es
Alfonso Otero, MD, PhD
34988385625
Alfonso.Otero.Gonzalez@sergas.es
Complexo Hospitalario Universitario de Ourense
Interventions
  • Procedure: Treatment of elevated asleep SBP mean — To reduce asleep SBP mean determined by 48h ambulatory blood pressure monitoring up to the randomly assigned target by hypertension treatment intensification when required
Study Locations (9 sites)
Complexo Hospitalario Universitario de Ourense, Ourense, Orense 32005 Spain
CS A Estrada, A Estrada, Pontevedra 26680 Spain
CS Panxón, Nigrán, Pontevedra 36340 Spain
Centro de Salud de A Doblada, Vigo, Pontevedra 36205 Spain
Centro de Salud de Bembrive, Vigo, Pontevedra 36214 Spain
Centro de Salud de Sardoma, Vigo, Pontevedra 36214 Spain
CS Teis, Vigo, Pontevedra 36216 Spain
Bioengineering & Chronobilogy Labs., University of Vigo, Vigo, Pontevedra 36310 Spain
CS San Roque, Vilagarcía de Arousa, Pontevedra 36600 Spain
Eligibility Criteria
Inclusion Criteria: 1. Men and women aged ≥18 years. 2. All participants must: (i) have at randomization sleep-time hypertension according to the current ESH/ESC guidelines, i.e., asleep SBP mean ≥120 mmHg;1 (ii) adhere to a routine of daytime activity and nighttime sleep; and (iii) provide their written informed consent to participate into the study. Exclusion Criteria: 1. Pregnancy. 2. History of drug/alcohol abuse within the last two years. 3. Night/shift-work employment. 4. Previous history of a systemic autoimmune disease or AIDS. 5. Evidence of a secondary form of hypertension, including coarctation of the aorta, hyperaldosteronism, renal artery stenosis, or pheochromocytoma 6. CVD disorders (unstable angina pectoris, heart failure, life-threatening arrhythmia, atrial fibrillation, kidney failure, and grade III-IV retinopathy). Previous CVD events will not be exclusionary if full physical and work activities are maintained. 7. Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of any drug, or, at the discretion of the investigator, might place the subject at higher risk from his/her participation in the study, or are likely to prevent the subject from complying with the requirements of the study or completing the trial period. 8. History of malignancy including leukemia and lymphoma (but not basal cell skin cancer), or any other severe, life-threatening disease within the past five years. 9. Inability to communicate and comply with all study requirements. 10. Intolerance to ABPM.
Conditions End Stage Renal Disease, Hypertension, E...
Phase NA
Enrollment 69
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Kidney failure has been recognized as one of the most costly chronic conditions among United States Veterans. Approximately 13,000 Veterans develop kidney failure each year, and most require hemodialysis initiation. Hemodialysis patients suffer significantly increased risk of death and hospitalizations, and excessive body fluid is a major cause of this. While empiric aggressive fluid removal during dialysis is one approach to limit fluid overload, this can cause dangerous decreases in blood pressure during dialysis that independently contribute to the high death rate. In this study, I aim to test a new strategy that prescribes fluid removal based on a patient's recent blood pressure patterns during dialysis. This clinical trial will compare my strategy to standard care and assess the outcomes of overall blood pressure change between dialysis treatments in addition to the number of times the blood pressure becomes dangerously low during dialysis. Another aim is to determine how differences in the structure and function of the heart influence blood pressure during dialysis.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: IBPS-Guided Ultrafiltration — Each month, the study investigator will review the average intradialytic blood pressure slope from the prior two weeks. A prespecified algorithm will be used to prescribe additional fluid removal/weight reduction based on this slope.

Primary Outcomes

  • Ambulatory Systolic Blood Pressure (4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-02-10
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 69 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Peter Noel Van Buren, MD (PRINCIPAL_INVESTIGATOR) - VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Contact Information
Study Contact:
Peter N Van Buren, MD
(214) 857-2214
peter.vanburen@va.gov
Peter N Van Buren, MD
(214) 857-2214
peter.vanburen@va.gov
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Peter Noel Van Buren, MD
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Interventions
  • Other: IBPS-Guided Ultrafiltration — Each month, the study investigator will review the average intradialytic blood pressure slope from the prior two weeks. A prespecified algorithm will be used to prescribe additional fluid removal/weight reduction based on this slope.
Study Locations (1 sites)
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas 75216-7167 United States
Eligibility Criteria
Inclusion Criteria: * Hemodialysis patient * Pre-dialysis systolic blood pressure greater than 140 mmHg averaged over 2 weeks OR post-dialysis systolic blood pressure greater than 130 mmHg averaged over 2 weeks Exclusion Criteria: * HemoDialysis Vintage Less than 2 months * Pregnancy * Mean systolic blood pressure nadir \<95 mmHg in 2 weeks screening * Mean pre- or post-dialysis systolic blood pressure \>180 mmHg * Mean pre to post-HD decrease in blood pressure \>60 mmHg * Routine intradialytic clonidine use * Routine intradialytic midodrine use * Documented antihypertensive medication non-adherence * Mean ultrafiltration rate \>13 mL/kg/hr during 2 week screening * For bioimpedance measurements only: amputation of a major extremity, presence of cardiac defibrillator or pacemaker, presence of a metallic implant (prosthetic joint)
Conditions Pulmonary Hypertension
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA. PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH). Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose. To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: PET/MR with 18F-FDG — (18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.

Primary Outcomes

  • Change of FDG uptake of heart (at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy)
  • Change of FDG uptake of lungs (at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy)
  • Change of the heart function (at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy)
  • Change of the lung perfusion (before radiotherapy and up to 16 weeks after completion of radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-06-01
Completion: 2027-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Health Network, Toronto
Principal Investigators:
  • Patrick Veit-Haibach, MD (PRINCIPAL_INVESTIGATOR) - University Health Network, Toronto
Contact Information
Study Contact:
Patrick Veit-Haibach, MD
416-340-4800
Patrick.Veit-Haibach@uhn.ca
Andrew Hope, MD
416-946-2124
Andrew.Hope@rmp.uhn.ca
Patrick Veit-Haibach
University Health Network
Interventions
  • Drug: PET/MR with 18F-FDG — (18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
Study Locations (1 sites)
University Health Network, Toronto, Ontario M5G 2M9 Canada
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy * Intention to treat with radio(chemo)therapy with incidental cardiac irradiation of at least 25Gy. * A negative urine or serum pregnancy test within the two week interval immediately prior to imaging, in women of child-bearing age. * Ability to provide written informed consent to participate in the study (for all components of the trial: imaging with cardiac PET/MR, blood sampling for plasma metabolomics and circulating DNA). Exclusion Criteria: * Contraindication for MR as per current institutional guidelines. * Contraindication for Gadolinium injection as per current institutional guidelines. * Inability to lie supine for at least 45 minutes. * Any patient who is pregnant or breastfeeding. * Any patient with known hypersensitivity to 18F-FDG.
Conditions Gestational Hypertension, Hypertension i...
Phase PHASE4
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This trial is a pilot-scale, single institution randomized, placebo-controlled trial to assess the feasibility, acceptability, and efficacy of administering dapagliflozin for cardiovascular risk reduction in the postpartum period. The target population is patients at high risk of adverse cardiovascular outcomes within five years post-delivery. Eligible participants will be randomized to receive either: 1) dapagliflozin (10mg daily) for six months (DAPA group) or 2) an orally administered, daily placebo (Control group). The study hypothesizes: The dapagliflozin group will have higher cardiovascular risk reduction scores than the Control Group.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Placebo — Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
  • Drug: Dapagliflozin 10mg Tab — Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.

Primary Outcomes

  • Cardiovascular risk reduction score (Baseline, 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-03-02
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan
Collaborators: Society for Maternal-Fetal Medicine Foundation, American Association of Obstetricians and Gynecologists Foundation
Principal Investigators:
  • Ashley Hesson, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Michigan
Contact Information
Study Contact:
Levi Anderson
734-763-0295
levijand@umich.edu
Levi Anderson
734-763-0295
levijand@umich.edu
University of Michigan
Ashley Hesson, MD, PhD
University of Michigan
Interventions
  • Drug: Placebo — Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
  • Drug: Dapagliflozin 10mg Tab — Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
Study Locations (1 sites)
University of Michigan, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * Admitted for delivery at the University of Michigan (UM) Labor and Delivery (L\&D) unit or enrolled in the UM postpartum blood pressure monitoring program following a delivery at the UM L\&D unit * Determined to be at least 23 and 0/7 weeks of gestation based on a clinically acceptable dating method (can be a single or multifetal gestation with or without the presence of fetal anomalies) at the time of delivery * Consents to participation and must understand/read/speak English with the ability to understand and willingness to sign a written informed consent in English * Diagnosed with a hypertensive pregnancy by either of the following criteria: * Taking an antihypertensive medication for the diagnosis of chronic or essential hypertension at the time of admission * Hypertension, chronic hypertension, or essential hypertension must be present in the prospective participant's medical record * Antihypertensive" can be any medication taken for the purpose of blood pressure control per the medical record * A documented hypertensive disorder of pregnancy (gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, superimposed preeclampsia, or eclampsia) prior to delivery * Eligible participants must report a planned contraceptive method as part of the consent process, to be noted on their consent document. * Has two or more blood pressures ≥160/110 Millimeters of mercury (mmHg) at least 60 minutes apart * If an admitted patient does not meet this blood pressure criterion but is otherwise eligible, participants can consent to have a BNP drawn within 12 hours of delivery as an alternative measure of cardiovascular risk (if the brain natriuretic peptide (BNP) is ≥100 Picograms per milliliter (pg/ml), participants are eligible to participate) Exclusion Criteria: * Non-English speaking * Ongoing pregnancy * Stated desire to become pregnant within 8 months post-delivery * Intention to breastfeed after enrollment * BNP ≥1000 pg/ml within 12 hours of delivery, clinical team to be notified of result * Comorbidities that may affect cardiovascular risk assessment (per protocol) * Contraindication to dapagliflozin (per protocol)
Conditions Intrahepatic Cholangiocarcinoma (Icc)
Phase Not Applicable
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This multicenter real-world study assesses the efficacy and safety of adjuvant therapies in postoperative intrahepatic cholangiocarcinoma (ICC) patients with high-risk recurrence factors. 90 eligible patients will be assigned to: Cohort 1: GP (gemcitabine/cisplatin) + adebrelimab Cohort 2: Apatinib + adebrelimab Cohort 3: S-1 (tegafur/gimeracil/oteracil) + adebrelimab Outcomes will be compared against historical real-world controls receiving standard chemotherapy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Adebrelimab — Adebrelimab administered intravenously at \[1200mg\] on day 1 of each 21-day cycle, for up to 17 cycles, common to all three cohorts.
  • Drug: Gemcitabine — Gemcitabine administered intravenously at \[1000 mg/m\^2\] on days 1 and 8 of each \[21\]-day cycle, for up to 8 cycles, in combination with cisplatin and adebrelimab,
  • Drug: Cisplatin — Cisplatin administered intravenously at \[25 mg/m\^2\] on days 1 and 8 of each \[21\]-day cycle, for up to 8 cycles, in combination with gemcitabine and adebrelimab.
  • Drug: S-1 — S-1 (tegafur/gimeracil/oteracil) administered orally twice daily on days 1-14 of each 21-day cycle, dosed according to body surface area, for up to 8 cycles, in combination with adebrelimab.
  • Drug: Apatinib — Apatinib administered orally at \[250mg\] once daily continuously, for up to 17 cycles, in combination with adebrelimab.

Primary Outcomes

  • Recurrence-Free Survival (RFS) (Through study completion, an average of 4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-04
Completion: 2029-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking Union Medical College Hospital
Principal Investigators:
  • Shunda Du (PRINCIPAL_INVESTIGATOR) - Peking Union Medical College Hospital (PUMCH)
  • Mei Guan (PRINCIPAL_INVESTIGATOR) - Peking Union Medical College Hospital (PUMCH)
Contact Information
Study Contact:
Baoluhe Zhang
010-69152831
dushd@pumch.cn
Baoluhe Zhang
010-69152831
dushd@pumch.cn
Peking Union Medical College Hospital (PUMCH)
Interventions
  • Drug: Adebrelimab — Adebrelimab administered intravenously at \[1200mg\] on day 1 of each 21-day cycle, for up to 17 cycles, common to all three cohorts.
  • Drug: Gemcitabine — Gemcitabine administered intravenously at \[1000 mg/m\^2\] on days 1 and 8 of each \[21\]-day cycle, for up to 8 cycles, in combination with cisplatin and adebrelimab,
  • Drug: Cisplatin — Cisplatin administered intravenously at \[25 mg/m\^2\] on days 1 and 8 of each \[21\]-day cycle, for up to 8 cycles, in combination with gemcitabine and adebrelimab.
  • Drug: S-1 — S-1 (tegafur/gimeracil/oteracil) administered orally twice daily on days 1-14 of each 21-day cycle, dosed according to body surface area, for up to 8 cycles, in combination with adebrelimab.
  • Drug: Apatinib — Apatinib administered orally at \[250mg\] once daily continuously, for up to 17 cycles, in combination with adebrelimab.
Study Locations (1 sites)
Peking Union Medical College Hospital (PUMCH), Beijing, China
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed ICC within 12 weeks after curative resection * Any T stage; N0/N+; M0. * At least one high-risk factor: Preoperative tumor penetration of the liver capsule or extrahepatic direct invasion; Preoperative imaging showing multifocal lesions or a single lesion \>5 cm; Vascular invasion (preoperative or postoperative pathology); Regional lymph node metastasis. * No prior systemic therapy for ICC. * ECOG performance status 0-2. * Expected survival ≥3 months. * Adequate organ function. * Agreement to use effective contraception (or surgical sterilization) during the study and for 120 days after the last dose. * Signed informed consent and anticipated good compliance with the study protocol. Exclusion Criteria: * Immunosuppressive therapy within 28 days prior to enrollment (excluding topical/inhaled corticosteroids or physiologic steroid doses ≤10 mg/day prednisone equivalent). * Systemic anticancer herbs/immunomodulators (e.g., thymosin, interferons) within 4 weeks, except for pleural effusion control. * Uncontrolled cardiovascular disease: Unstable angina/myocardial infarction Arrhythmias with QTc ≥450 ms (men) or ≥470 ms (women) NYHA Class III-IV heart failure or LVEF \<50% * Active infections (IV antibiotics/antivirals required) or fever \>38.5°C within 4 weeks; or major surgery within 3 weeks. * Active autoimmune/immunodeficiency diseases (e.g., hepatitis, pneumonitis, rheumatoid arthritis), except: Hypothyroidism on stable hormone replacement Type 1 diabetes with controlled glucose Uncontrolled asthma requiring systemic bronchodilators (resolved childhood asthma allowed). \- Active infections: HIV/AIDS HBV (DNA ≥500 IU/mL) or HCV (RNA-positive) unless: HBV DNA \<500 IU/mL + antiviral therapy ≥14 days * Prior/proposed organ transplantation (excluding corneal grafts). * Concurrent interventional trials or investigational drugs within 4 weeks without recovery to Grade ≤1 toxicity. * Hypersensitivity to study drug components. * Allogeneic transplant history/plans. * Uncontrolled psychiatric/substance abuse disorders. * Refractory hypertension (≥140/90 mmHg despite treatment). * Clinically significant bleeding/thromboembolism: GI bleeding within 3 months Thrombotic events within 6 months (stroke, DVT/PE) * Coagulopathy (INR \>1.5, PT \>ULN+4s, aPTT \>1.5×ULN) or anticoagulant use. * Proteinuria ≥++ on dipstick or 24-h urine protein ≥1 g. * Other high-risk conditions per investigator judgment.
Conditions Glaucoma
Phase Not Applicable
Enrollment 352
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn whether personality traits are related to eye side effects from glaucoma medications in adults who currently use or previously used these medications. The main questions this study aims to answer are: Are certain personality traits associated with the occurrence or severity of eye side effects from glaucoma medications? Do personality traits differ between people who experience these side effects and those who do not? Participants will complete a questionnaire that measures five personality traits: openness, conscientiousness, extraversion, agreeableness, and neuroticism. They will also provide basic demographic information. The researchers will review participants' medical records to collect information about their glaucoma medications and any related eye side effects, including the type and frequency of side effects and whether treatment was changed because of them. Participation involves one session lasting approximately 30 minutes. Questionnaires may be completed securely online or in person at the clinic. The study will include approximately 352 adults. No treatment will be assigned or changed as part of this study.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: No Interventions — There is no intervention

Primary Outcomes

  • Difference in Five-Factor Model neuroticism scores between participants with and without significant ocular adverse reactions (Assessed once during the single study session, lasting approximately 30 minutes.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-25
Completion: 2027-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 352 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Principal Investigators:
  • Hady Saheb, MD MPH (PRINCIPAL_INVESTIGATOR) - MUHC RI
Contact Information
Study Contact:
Ana Hernandez, MD
15149341934
ana.ramirezhernandez@mail.mcgill.ca
Hady Saheb, MD MPH
514-934-1934
hady.saheb@mcgill.ca
Ana Hernandez, MD
514-934-1934
ana.ramirezhernandez@mail.mcgill.ca
McGill University Health Center
Interventions
  • Other: No Interventions — There is no intervention
Study Locations (1 sites)
McGill University Health Center, Montreal, Quebec Canada
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * Diagnosis of glaucoma. * Current or previous treatment with one or more glaucoma medications. * Able to provide informed consent. * Able to complete the study questionnaires in English or French. Exclusion Criteria: * Uncontrolled anxiety or depression that was present before glaucoma medication treatment began. * Unable to provide informed consent. * Unable to complete the study questionnaires in English or French.
Conditions Chronic Pulmonary Thromboembolism
Phase Not Applicable
Enrollment 500
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The project is a national, prospective, multicenter, observational pilot project of screening CTEPH in pacients after APE in the Czech Republic. The main goal of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of Chronic tromboembolic pulmonary hypertesion in such a way as to ensure the maximum positive impact on the health of the population and high cost-effectiveness of the whole process.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Standardized CTEPH Screening Protocol — Implementation of a standardized screening algorithm for early detection of CTEPH in patients after Acute Pulmonary Embolism (APE) and establishment of optimized referral of patients to specialized centers.

Primary Outcomes

  • Positive predictive value of initial examination (Up to six months from enrollment)
  • CTEPH detection rates (Up to six months from enrollment)
  • Proportion of people with suspected CTEPH who attended a follow-up examination at a specialized pulmonary hypertension treatment centre (Up to six months from enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-07
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute of Health Information and Statistics of the Czech Republic
Collaborators: General University Hospital, Prague
Principal Investigators:
  • Pavel Jansa, prof. (STUDY_DIRECTOR) - General University Hospital of Prague
Contact Information
Study Contact:
Kateřina Ondrášková, Msc
604603143
katerina.ondraskova@uzis.cz
Lucie Mandelová, PhD
lucie.mandelova@uzis.cz
Marián Felšöci, M.D.
felsoci.marian@fnbrno.cz
Brno University Hospital
Interventions
  • Other: Standardized CTEPH Screening Protocol — Implementation of a standardized screening algorithm for early detection of CTEPH in patients after Acute Pulmonary Embolism (APE) and establishment of optimized referral of patients to specialized centers.
Study Locations (10 sites)
Brno University Hospital, Brno, Czechia
Havlíčkův Brod Hospital, Havlíčkův Brod, Czechia
University Hospital Hradec Králové, Hradec Králové, Czechia
Jihlava Hospital, Jihlava, Czechia
Náchod Hospital, Náchod, Czechia
University Hospital Olomouc, Olomouc, Czechia
University Hospital Ostrava, Ostrava, Czechia
Pardubice Hospital, Pardubice, Czechia
Rychnov nad Kněžnou Hospital, Rychnov nad Kněžnou, Czechia
Tábor Hospital, Tábor, Czechia
Eligibility Criteria
Inclusion Criteria: * Age over 18 years * Signed consent to participate in the project and GDPR * Patients with an episode of acute pulmonary embolism in the last 3-12 months, with ongoing anticoagulation therapy: 1. Patients with new-onset and ongoing or progressive dyspnea (min. NYHA II) after a pulmonary embolism episode or worsening of dyspnea after a pulmonary embolism episode compared to the status before the episode (at least 1 HYHA grade) or 2. Asymptomatic patients after a pulmonary embolism episode and at least one of the following risk factors: * ECHO evidence of severe PH at diagnosis of PE (PASP \>60 mmHg) * Antiphospholipid syndrome with triple positivity (presence of lupus anticoagulans + anti-beta-2-glycoprotein I (B2GPI) antibodies + anticardiolipin) * Infected permanent venous inlets and cardiac pacing/defibrillation intravascular systems * Presence of ventriculoatrial shunt for treatment of hydrocephalus * Nonspecific intestinal inflammation (ulcerative colitis, Crohn's disease) * History of splenectomy * Myeloproliferative disorders * Chronic osteomyelitis Exclusion Criteria: * Not agreeing to participate in the project * Contraindications to treatment
Conditions Aorto Iliac Occlusive Disease, Blood Pre...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Hypertension is a major risk factor for a variety of cardiovascular diseases. When hypertension results from increased vascular resistance due to a narrowing of the descending aorta, it can be effectively treated with stenting. More recently, evidence suggest that stenting in more distal parts of the arterial vascular bed is also associated with a reduction in blood pressure. The investigators hypothesize that stenting of occlusions more distal of the descending aorta decreases the central blood pressure and afterload as reflected by NT-proBNP (N-terminal pro-Brain Natriuretic Peptide), a biomarker of intracardiac pressures and predictor of heart failure events. The goal of this pilot study is to prospectively investigate changes in blood pressure after stent placement in the aorto-iliac region.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Stent placement — Patients with an aorto-iliac occlusion will receive a stent, according to standard care

Primary Outcomes

  • The primary objective is to describe the changes in arterial blood pressures between baseline and 12 months follow-up after endovascular treatment of an occlusion of the infrarenal aorta and/or common iliac arteries. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-30
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rijnstate Hospital
Contact Information
Study Contact:
Michel Reijnen, prof.dr.
0031 88 005 7282
vascularsurgery@rijnstate.nl
Michel Reijnen, prof
0880057282
vascularsurgery@rijnstate.nl
Rijnstate
Interventions
  • Procedure: Stent placement — Patients with an aorto-iliac occlusion will receive a stent, according to standard care
Study Locations (1 sites)
Rijnstate, Arnhem, 6815AD Netherlands
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Singed informed consent * Chronic occlusion in the infrarenal aorta and/or one or both common iliac arteries * Total lesion length of ≥30mm * Clinical indication for treatment of the pathology (Chronic limb threatening ischemia or disabling intermittent claudication not responding to supervised exercise training) Exclusion Criteria: * Patient is unable to understand the study requirements and/ or is unwilling to adhere to the follow-up * Juxtarenal pathology (\<2cm below the lowest renal artery) * Acute occlusion of the target area (Acute Leriche Syndrome) * Embolic disease
Conditions Hypertension, Ischemic Heart Disease, Va...
Phase Not Applicable
Enrollment 8000
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical investigation will evaluate a novel contactless technology for assessing arterial stiffness and explore its potential in assessment of risk for and development of cardiovascular disease. The main aims of the study are: 1. To assess device and method performance for assessment of arterial stiffness and cardiovascular risk, on a prospective primary care cohort. 2. To see if precision may be added in CVD risk assessment through a multi-modal approach, combining data on macro- and micro-circulatory function.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Correlation between vibrometer-based PWV and ultrasound-based PWV (Typically same day or within 3-6 months of enrolment, at extended visit. If attending a 1-year follow-up, then around 1 year and 3-6 months from enrolment (follow-up extended visit).)
  • Assess associations between vibrometer measurements and clinical measures of increased cardiovascular risk (Typically within 3 months of initial visit and enrolment, at extended visit. If attending a 1-year follow-up, then around 1 year and 3 months from enrolment.)
  • Assess prediction performance of increased cardiovascular risk when combining vibrometer measurements, brachial BP, ABI and ECG in prediction models (Typically within 3-6 months of enrolment (extended visit). If attending a 1-year follow-up, then around 1 year and 3 months from enrolment (follow-up extended visit)..)
  • Assess performance of a multimodal risk score using data from the current study and the in parallel performed investigation "Spectrum 1" (CIV ID: CIV-22-07-039907). (Typically within 3-6 months after enrolment (extended visit). May include 1-year follow-up, in which case 1 year and 3-6 months (follow-up extended visit).)
  • Assess associations between vibrometer measurements and presence of aortic valve pathology (Typically within 3-6 months of enrolment, at extended visit. If attending a 1-year follow-up, then around 1 year and 3-6 months from enrolment (follow-up extended visit).)
  • Assess associations between vibrometer measurements and ankle-brachial index (Typically at initial visit, same day as enrolment. If attending a 1-year follow-up, then around 1 year from enrolment.)
  • Assess associations between vibrometer measurements and measure of increased cardiovascular risk by risk score (Typically at initial visit, same day as enrolment. If attending a 1-year follow-up, then around 1 year from enrolment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-02-01
Completion: 2026-02-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 8000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: HJN Sverige AB/Neko Health
Principal Investigators:
  • Henrik Hellqvist, MD (PRINCIPAL_INVESTIGATOR) - Neko Health AB
Contact Information
Study Contact:
Mattias Windå, MSc
+46703169040
mattias@nekohealth.com
Andreea Valdman, MD
+4673 939 27 11
andreea@nekohealth.com
Atrium Health Care Centre
Henrik Hellqvist, MD
Atrium Health Care Centre
Interventions
N/A
Study Locations (3 sites)
Atrium Health Care Centre, Stockholm, Sweden
Neko Health Centre, Regeringsgatan, Stockholm, Sweden
Neko Health Centre, Sibyllegatan, Stockholm, Sweden
Eligibility Criteria
Inclusion criteria: * Adult patients that are part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation. * Patients with signed informed consent Exclusion criteria: * Cognitive impairment * Patients unable to understand the oral and written study information in Swedish or English * Other severe disorder or terminal disease, e.g. infection/sepsis, severe COPD or metastatic cancers. * Patients unable to provide an informed consent
Conditions Hypertension
Phase NA
Enrollment 255
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The present study, OBPM\_COYOTE2024, with N = 255 participants minimum over 1 visit (lasting \~15min), has been designed to collect raw optical data with Aktiia.product-G2C Clinical investigational device together with Aktiia G2 Bracelet and Aktiia Init I1 oscillometric cuff within a cohort of subjects characterized by a wide variety of phenotypes. The resulting dataset will support research and development activities conducted by AKTIIA SA out of the study context.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Aktiia G2C — Study subjects are asked to stay seated while 3 successive measurements are taken with the Aktiia G2C device under investigation (BP and PR) and two references (Aktiia Bracelet G2 and Aktiia Init I1 oscillometric cuff).

Primary Outcomes

  • Data set build (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-20
Completion: 2026-12-31
Eligibility
Age: 21 Years – 85 Years
Sex: ALL
Volunteers: true
Enrollment: 255 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aktiia SA
Contact Information
Study Contact:
Pascale Vermare
+41 32 552 20 52
pascale.vermare@aktiia.com
Grégoire WUERZNER, Prof. Med.
+41 21 314 02 23
gregoire.wuerzner@chuv.ch
CHUV Service de Néphrologie et d'Hypertension
Interventions
  • Device: Aktiia G2C — Study subjects are asked to stay seated while 3 successive measurements are taken with the Aktiia G2C device under investigation (BP and PR) and two references (Aktiia Bracelet G2 and Aktiia Init I1 oscillometric cuff).
Study Locations (1 sites)
CHUV Service de Néphrologie et d'Hypertension, Lausanne, 1011 Switzerland
Eligibility Criteria
Inclusion Criteria: * Subjects aged 21 to 85yo * Subjects or witnesses fluent in written and spoken French * Subjects agreeing to attend the study visit and follow study procedures * Subjects that have signed the informed consent form. Exclusion Criteria: * Amputated index fingers * Damaged/injured skin at index fingers * Damaged/injured skin at wrists * Subjects with tachycardia (heart rate at rest \> 120bpm) * Subjects with atrial fibrillation * Subjects with diabetes * Subjects with marked renal dysfunctions (eGFR \< 30mL/min/1.73 m2) * Subjects with untreated hyper-/hypothyroidism * Subjects with pheochromocytoma * Subjects with Raynaud's disease * Subjects with an arteriovenous fistula * Women in known pregnancy * History of polyneuropathy